StockSelector.com
  Research, Select, & Monitor Saturday, April 29, 2017 1:35:08 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
   Diversify with StockSelector.com
- the tools for short-term traders and long-term investors to find successful ideas to fit their strategies and to keep informed of the stocks you follow or hold. Take a macro look at the market and by industry, narrow down to specific stocks and the right time, then use our portfolio to monitor the stocks and be alerted of changes.


 Sector ETF's Price Change  
S&P 500 Consumer Discretionary Sector SPDR 90.06 (0.40%)
S&P 500 Consumer Staples Sector SPDR 55.18 (0.04%)
S&P 500 Energy Sector SPDR 67.84 0.07%
S&P 500 Financials Sector SPDR 23.53 (0.97%)
S&P 500 Health Care Sector SPDR 75.50 0.27%
S&P 500 Industrial Sector SPDR 66.34 (0.47%)
S&P 500 Materials Sector SPDR 53.07 (0.84%)
S&P 500 Information Technology Sector SPDR 54.38 0.26%
S&P 500 Utilities Sector SPDR 51.70 (0.48%)

 Most Oversold Industry
 Auto Manufacturers - Major
These firms are some of the largest vehicle manufacturers in the world. They produce the obvious cars, trucks, buses, vans, and motorcycles. Recreational vehicles, mini-vans, luxury cars, components, and construction equipment are some of their other related items on the production lines. Many firms also offer financing of their goods and in a field tied to vehicle financing, one firm here offers mortgages and even auto and homeowner's insurance. They typically sell their product to the consumer through auto dealerships located domestically and abroad.


Exxon Mobil Beats By Two Cents
4/28/2017 8:00:06 AM



0.48%
Exxon Mobil Corp. (XOM) reported first quarter earnings of $0.95 per share on revenue of $63.29 billion. The consensus earnings estimate was $0.85 per share on revenue of $68.78 billion for the quarter ending March 31, 2017. The Earnings ... more

Mattel Misses More than Expected
4/20/2017 4:09:00 PM


0.66%
Mattel, Inc. (MAT) reported first quarter loss of $0.32 per share on revenue of $735.60 million. The consensus estimate was a loss of $0.17 per share on revenue of $810.2 million for the quarter ending March 31, 2017. The Earnings Whisper ... more

Travelers Misses More Than Expected
4/20/2017 6:57:01 AM


0.41%
Travelers Companies, Inc. (TRV) reported first quarter earnings of $2.16 per share on revenue of $6.94 billion. The consensus earnings estimate was $2.40 per share on revenue of $6.82 billion for the quarter ending March 31, 2017. The ... more

IBM Reports In-line
4/18/2017 4:06:00 PM


0.02%
International Business Machines Corp. (IBM) reported first quarter earnings of $2.38 per share on revenue of $18.16 billion. The consensus earnings estimate was $2.34 per share on revenue of $18.49 billion for the quarter ending March ... more

Intuitive Surgical Misses by a Penny
4/18/2017 4:05:16 PM


0.08%
Intuitive Surgical, Inc. (ISRG) reported first quarter earnings of $5.09 per share on revenue of $674.2 million. The consensus earnings estimate was $4.83 per share on revenue of $659.5 million for the quarter ending March 31, 2017. ... more

Netflix Reports In-line
4/17/2017 4:05:00 PM


0.57%
Netflix, Inc. (NFLX) reported second quarter earnings of $0.40 per share on revenue of $2.64 billion. The consensus earnings estimate was $0.38 per share on revenue of $2.64 billion for the quarter ending June 30, 2017. The Earnings ... more

 StockSelector's Top Ranked Stock
 Yelp Inc.
Positive Points:13
Negative Points:7
Yelp, Inc. is a website engaged in providing information through online community offering social networking. It covers restaurants, shopping, nightlife, financial services, health and a variety of services. The company serves customers in the United States, Canada, the United Kingdom, Ireland, France, Germany, Austria, the Netherlands, Spain, Italy, Switzerland and Belgium. Yelp, Inc. is headquartered in San Francisco, California.

 Potential Breakout Stock
 Progenics Pharmaceuticals Inc.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.











Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Quotes are delayed by 15-20 minutes. Quotes provided by QuoteMedia

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2017 StockSelector.com. All rights reserved.